
Femasys Inc.
FEMYNASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$2.97
+US$0.23 · +8.42%
FEMY公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
66
Undervalued
動能
17
Strong Down
情緒
49
Mixed
風險韌性
34
High Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
- 產業
- Medical - Instruments & Supplies
- 部門
- Healthcare
- 總部
- US
- 執行長
- Kathy Lee-Sepsick
- 上市以來
- 2021年6月18日
- 僱員
- 53
市場位置
- 成交量
- 58.49萬
- 6.77× 平均值
- 平均成交量
- 8.64萬
- 日均成交量
- 市值
- 893.78萬 USD
- 貝塔
- -2.09
- 市場參考 1
繼續GoAI的研究
在 GoAI 中研究FEMYresearch.disclaimer